Rosekeila Simões Nomelini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rosekeila Simões Nomelini has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Eddie Fernando Candido Murta
Department of Gynecology and Obstetrics, Laboratory of Applied Sciences for Women (LaCam), Federal University of Triângulo Mineiro, Uberaba, Brazil
23 shared publications- Eddie Fernando Candido Murta
Universidade Federal do Triângulo Mineiro, Brazil
21 shared publications Millena Prata Jammal
Department of Gynecology and Obstetrics, Laboratory of Applied Sciences for Women (LaCam), Federal University of Triângulo Mineiro, Uberaba, Brazil
17 shared publicationsAgrimaldo Martins-Filho
Univ Fed Triangulo Mineiro, Dept Gynecol & Obstet, Lab Appl Sci Women LaCam, Ave Getulio Guarita 214, BR-38025440 Uberaba, MG, Brazil
8 shared publicationsDouglas Côbo Micheli
Discipline of Pharmacology Federal University of Triângulo Mineiro Uberaba Brazil
6 shared publicationsRenata Margarida Etchebehere
Surgical Pathology Service, Federal University of Triângulo Mineiro, Uberaba, Brazil
6 shared publications
Latest Publications
- 15 September 2026
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
Stromal Expression of TNF-α and Its Receptors TNFR1 and TNFR2: Association with Blood Count Parameters in Ovarian Cancer
The objective of this study was to evaluate the association between immunostaining of tumor necrosis factor-alpha (TNF-α) and its receptors in the stroma of malignant ovarian neoplasm with hemogram parameters and tumor markers. Women with a confirmed diagnosis of malignant or borderline ovarian neoplasm were included ( n = 43). Age, hormonal status, histological type, histological grade, staging, type of carcinogenesis, and blood count parameters were recorded. For the immunohistochemical study, TNF-α and its receptors were evaluated in peritumoral stroma. Receiver operating characteristic curve and multivariate analysis were performed. The level of significance was 0) and neutrophils (cutoff value ≤3,900) between strong and weak immunostaining. In relation to TNF-α receptor 1 (TNFR1), a cutoff value of monocytes >312 per mm 3 was found. Regarding TNF-α receptor 2 (TNFR2), the cutoff value of CA-125 was ≤95.16 U/mL. Still regarding TNFR2, the cutoff value for the absolute platelet count was ≤298,000 per mm 3 . Multivariate analysis showed that an absolute monocyte count >312 per mm 3 is associated with strong stromal immunostaining of TNFR1, and a platelet count ≤298,000 per mm 3 is associated with strong stromal immunostaining of TNFR2. Therefore, an absolute monocyte count >312 per mm 3 is associated with strong stromal immunostaining of TNFR1, and a platelet count ≤298,000 per mm 3 is associated with strong stromal immunostaining of TNFR2.
- 15 September 2026
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
Stromal Expression of TNF-α and Its Receptors TNFR1 and TNFR2: Association with Blood Count Parameters in Ovarian Cancer
The objective of this study was to evaluate the association between immunostaining of tumor necrosis factor-alpha (TNF-α) and its receptors in the stroma of malignant ovarian neoplasm with hemogram parameters and tumor markers. Women with a confirmed diagnosis of malignant or borderline ovarian neoplasm were included ( n = 43). Age, hormonal status, histological type, histological grade, staging, type of carcinogenesis, and blood count parameters were recorded. For the immunohistochemical study, TNF-α and its receptors were evaluated in peritumoral stroma. Receiver operating characteristic curve and multivariate analysis were performed. The level of significance was 0) and neutrophils (cutoff value ≤3,900) between strong and weak immunostaining. In relation to TNF-α receptor 1 (TNFR1), a cutoff value of monocytes >312 per mm 3 was found. Regarding TNF-α receptor 2 (TNFR2), the cutoff value of CA-125 was ≤95.16 U/mL. Still regarding TNFR2, the cutoff value for the absolute platelet count was ≤298,000 per mm 3 . Multivariate analysis showed that an absolute monocyte count >312 per mm 3 is associated with strong stromal immunostaining of TNFR1, and a platelet count ≤298,000 per mm 3 is associated with strong stromal immunostaining of TNFR2. Therefore, an absolute monocyte count >312 per mm 3 is associated with strong stromal immunostaining of TNFR1, and a platelet count ≤298,000 per mm 3 is associated with strong stromal immunostaining of TNFR2.
- 1 January 2026
- Published by Editora Cientifica Digital
- p. 53-58
Medicina fetal no Brasil: acompanhamento da mulher em gestações de alto risco e os Desafios do SUS
A medicina fetal representa um campo essencial dentro da assistência à saúde da mulher, especialmente no contexto das gestações de alto risco. No Brasil, o Sistema Único de Saúde (SUS) desempenha papel central na organização e oferta desse cuidado, enfrentando desafios estruturais, sociais e culturais que impactam diretamente os desfechos maternos e perinatais. Este capítulo discute a importância do acompanhamento especializado em medicina fetal, os principais determinantes sociais envolvidos, as desigualdades de acesso e os desafios na integralidade do cuidado. Também são abordadas estratégias para qualificação da assistência, considerando a transversalidade entre gênero, condições socioeconômicas e políticas públicas.
- 1 January 2026
- Published by Editora Cientifica Digital
- p. 53-58
Medicina fetal no Brasil: acompanhamento da mulher em gestações de alto risco e os Desafios do SUS
A medicina fetal representa um campo essencial dentro da assistência à saúde da mulher, especialmente no contexto das gestações de alto risco. No Brasil, o Sistema Único de Saúde (SUS) desempenha papel central na organização e oferta desse cuidado, enfrentando desafios estruturais, sociais e culturais que impactam diretamente os desfechos maternos e perinatais. Este capítulo discute a importância do acompanhamento especializado em medicina fetal, os principais determinantes sociais envolvidos, as desigualdades de acesso e os desafios na integralidade do cuidado. Também são abordadas estratégias para qualificação da assistência, considerando a transversalidade entre gênero, condições socioeconômicas e políticas públicas.
- 18 November 2025
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. 40 (4) , 223-229
The lack of ESR1 ethnic diversity evidence and its implications for breast cancer personalized treatment
The ESR1 gene encodes estrogen receptor alpha (ERα), whose central role in breast tumorigenesis has supported the development of endocrine therapies, including selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). Despite their proven efficacy, resistance, relapse, and treatment-limiting toxicity remain frequent, underscoring interindividual and interpopulation variability in therapeutic outcomes. Allelic diversity within ESR1 is a key determinant of these differences, as variant frequencies and distributions vary substantially across populations and ethnic groups. Associating ESR1 variants with genomic ancestry can help anticipate variability in drug response, thereby reducing adverse events and facilitating the clinical implementation of pharmacogenetics. Investigating population-specific differences that shape drug efficacy and toxicity not only generates evidence for groups historically underrepresented in genomic studies but also enhances the equity and global applicability of personalized medicine. In conclusion, genetic variation in ESR1 may modulate both the efficacy and safety of breast cancer therapies. Understanding the genetic diversity of populations worldwide is therefore essential for minimizing adverse effects, improving treatment outcomes, and advancing the implementation of pharmacogenetics in clinical practice.
- 18 November 2025
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. 40 (4) , 223-229
The lack of ESR1 ethnic diversity evidence and its implications for breast cancer personalized treatment
The ESR1 gene encodes estrogen receptor alpha (ERα), whose central role in breast tumorigenesis has supported the development of endocrine therapies, including selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). Despite their proven efficacy, resistance, relapse, and treatment-limiting toxicity remain frequent, underscoring interindividual and interpopulation variability in therapeutic outcomes. Allelic diversity within ESR1 is a key determinant of these differences, as variant frequencies and distributions vary substantially across populations and ethnic groups. Associating ESR1 variants with genomic ancestry can help anticipate variability in drug response, thereby reducing adverse events and facilitating the clinical implementation of pharmacogenetics. Investigating population-specific differences that shape drug efficacy and toxicity not only generates evidence for groups historically underrepresented in genomic studies but also enhances the equity and global applicability of personalized medicine. In conclusion, genetic variation in ESR1 may modulate both the efficacy and safety of breast cancer therapies. Understanding the genetic diversity of populations worldwide is therefore essential for minimizing adverse effects, improving treatment outcomes, and advancing the implementation of pharmacogenetics in clinical practice.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 17, 345-353
High-Grade Cervical Intraepithelial Neoplasia: Impact of Colposcopic Lesion Area on Systemic Immune Responses
Background: The progression of high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer is accompanied by a reduction in the immune response. The objectives of the study were to determine whether colposcopic lesion area is associated with serum levels of cytokines IL (interleukin) − 1, IL-6, IL-8, IL-10, IL-12 and TNF-α in precursor lesions of cervical cancer. Methods: The study population comprised patients with high-grade squamous intraepithelial lesion who had undergone colposcopy, cervical biopsy, and measurements of serum cytokines by ELISA (Enzyme-Linked Immunosorbent Assay). Genotyping for HPV (human papillomavirus) 16, 18, 45 and 52 was performed by PCR (Polymerase Chain Reaction). ROC (Receiver Operating Characteristic) curves were calculated to determine whether there existed a cut-off value for serum cytokines in patients with colposcopic lesion area smaller vs larger than 1 cm2. For cytokines with significant results, these cut-off values were used to perform the multivariable analysis. Results: There were 71 patients with CIN 2/3. ROC curves were calculated to verify a cut-off value for serum cytokine levels that could be used to distinguish between lesion areas < 1 cm2 vs ≥ 1 cm2. Values with statistical significance were IL-1 > 13.3 pg/mL and IL-12 ≤ 349.6 pg/mL. In the multivariable analysis, the independent variables associated with colposcopic lesion area greater than 1cm2 were IL-1> 13.3 pg/mL and IL-12 ≤ 349.6 pg/mL [OR (95% CI) = 10.10 (1.50– 67.96); OR (95% CI)=10.70 (1.17– 97.45), respectively]. Conclusion: Although CIN 2/3 is a local uterine cervix lesion, there is a systemic immunological response. Our results are unprecedented and could be the target of new important studies in public health and cervical cancer prevention.
- 1 February 2025
- Published by Taylor & Francis in International Journal of Women's Health
- Vol. ume 17, 345-353
Open AccessHigh-Grade Cervical Intraepithelial Neoplasia: Impact of Colposcopic Lesion Area on Systemic Immune Responses
Background: The progression of high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer is accompanied by a reduction in the immune response. The objectives of the study were to determine whether colposcopic lesion area is associated with serum levels of cytokines IL (interleukin) − 1, IL-6, IL-8, IL-10, IL-12 and TNF-α in precursor lesions of cervical cancer. Methods: The study population comprised patients with high-grade squamous intraepithelial lesion who had undergone colposcopy, cervical biopsy, and measurements of serum cytokines by ELISA (Enzyme-Linked Immunosorbent Assay). Genotyping for HPV (human papillomavirus) 16, 18, 45 and 52 was performed by PCR (Polymerase Chain Reaction). ROC (Receiver Operating Characteristic) curves were calculated to determine whether there existed a cut-off value for serum cytokines in patients with colposcopic lesion area smaller vs larger than 1 cm2. For cytokines with significant results, these cut-off values were used to perform the multivariable analysis. Results: There were 71 patients with CIN 2/3. ROC curves were calculated to verify a cut-off value for serum cytokine levels that could be used to distinguish between lesion areas < 1 cm2 vs ≥ 1 cm2. Values with statistical significance were IL-1 > 13.3 pg/mL and IL-12 ≤ 349.6 pg/mL. In the multivariable analysis, the independent variables associated with colposcopic lesion area greater than 1cm2 were IL-1> 13.3 pg/mL and IL-12 ≤ 349.6 pg/mL [OR (95% CI) = 10.10 (1.50– 67.96); OR (95% CI)=10.70 (1.17– 97.45), respectively]. Conclusion: Although CIN 2/3 is a local uterine cervix lesion, there is a systemic immunological response. Our results are unprecedented and could be the target of new important studies in public health and cervical cancer prevention.
- 25 October 2024
- Published by Care Comm in Česká gynekologie
- Vol. 89 (5) , 377-388
Evaluation of cytokine immunostaining in ovarian neoplasms and endometriomas
Objective: The objective of our study was to quantify and compare the immunostaining of IL-2, IL-5, IL-6, IL-8, and TNF-a in endometriomal tissue, non-neoplastic tumors, benign neoplasms, and malignant ovarian neoplasms. Materials and methods: The study involved 90 patients: 15 non-neoplastic ovarian lesions, 28 ovarian benign neoplasms, 28 ovarian malignant neoplasms, and 19 ovarian endometriomas were dia gnosed. Immunohistochemistry was performed for cytokines IL-2, IL-5, IL-6, IL-8, and TNF-alpha and their concentrations were compared in these groups. Fisher's exact test was used, requiring a P-value of < 0.05 for signifi cance. Results: IL-5 and IL-8 epithelial immunostaining is stronger in endometriomas than in ovarian cancer (P-values of 0.0046 and 0.0149, resp.). The stromal immunostaining of TNF-alpha, IL-5, IL-6, and IL8 is stronger in endometriomas than in ovarian cancer (P-values of 0.0008, < 0.0001, 0.0003, and 0.0006, resp.). Conclusions: Stronger immunostaining of some cytokines in endometriomas compared to ovarian cancer refl ects an infl ammatory and immune response that could be future targets for new discoveries about the infi ltrative behavior of endometriosis.
- 25 October 2024
- Published by Care Comm in Česká gynekologie
- Vol. 89 (5) , 377-388
Evaluation of cytokine immunostaining in ovarian neoplasms and endometriomas
Objective: The objective of our study was to quantify and compare the immunostaining of IL-2, IL-5, IL-6, IL-8, and TNF-a in endometriomal tissue, non-neoplastic tumors, benign neoplasms, and malignant ovarian neoplasms. Materials and methods: The study involved 90 patients: 15 non-neoplastic ovarian lesions, 28 ovarian benign neoplasms, 28 ovarian malignant neoplasms, and 19 ovarian endometriomas were dia gnosed. Immunohistochemistry was performed for cytokines IL-2, IL-5, IL-6, IL-8, and TNF-alpha and their concentrations were compared in these groups. Fisher's exact test was used, requiring a P-value of < 0.05 for signifi cance. Results: IL-5 and IL-8 epithelial immunostaining is stronger in endometriomas than in ovarian cancer (P-values of 0.0046 and 0.0149, resp.). The stromal immunostaining of TNF-alpha, IL-5, IL-6, and IL8 is stronger in endometriomas than in ovarian cancer (P-values of 0.0008, < 0.0001, 0.0003, and 0.0006, resp.). Conclusions: Stronger immunostaining of some cytokines in endometriomas compared to ovarian cancer refl ects an infl ammatory and immune response that could be future targets for new discoveries about the infi ltrative behavior of endometriosis.
- 30 August 2024
- Published by Care Comm in Česká gynekologie
- Vol. 89 (4) , 298-303
Endometrioid adenocarcinoma with sacral metastasis
Most bone tumors are metastatic. Breasts, lungs, kidneys, and thyroid are the primary sites most commonly involved in bone metastasis-type outcomes. This case study describes the involvement of a patient with a bone tumor located in the axial skeleton, initially in the sacral region. However, the primary site was undefined. Therefore, it was necessary to expand the investigation with immunohistochemistry, which demonstrated a metastatic tumor compatible with endometrioid adenocarcinoma. But even after examination, no active lesion was found in the endometrial region. The study was observational, descriptive, and aimed to discuss the importance of more specific investigative methods. In this context, immunohistochemistry stands out as an exquisite method capable of optimizing diagnosis, therapy, and consequently, prognosis. Key words: bone neoplasm – endometrioid adenocarcinoma – immunohistochemistry
- 30 August 2024
- Published by Care Comm in Česká gynekologie
- Vol. 89 (4) , 298-303
Endometrioid adenocarcinoma with sacral metastasis
Most bone tumors are metastatic. Breasts, lungs, kidneys, and thyroid are the primary sites most commonly involved in bone metastasis-type outcomes. This case study describes the involvement of a patient with a bone tumor located in the axial skeleton, initially in the sacral region. However, the primary site was undefined. Therefore, it was necessary to expand the investigation with immunohistochemistry, which demonstrated a metastatic tumor compatible with endometrioid adenocarcinoma. But even after examination, no active lesion was found in the endometrial region. The study was observational, descriptive, and aimed to discuss the importance of more specific investigative methods. In this context, immunohistochemistry stands out as an exquisite method capable of optimizing diagnosis, therapy, and consequently, prognosis. Key words: bone neoplasm – endometrioid adenocarcinoma – immunohistochemistry
- 1 July 2024
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 18 (7) , XC11-XC15
Differences in Stromal Immunostaining of Tumour Necrosis Factor-alpha and its Receptors in Neoplastic and Non Neoplastic Ovarian Lesions: A Cross-sectional Study
Introduction: Ovarian cancer has an unknown pathogenesis, and cytokines may play an important role in the aetiology and prognosis. Tumour Necrosis Factor-alpha (TNF-α) and its receptors (TNFR1 and TNFR2) are involved in the biology of ovarian cancer, tumour pathogenesis, and their relationship with prognostic factors. They are involved in biological processes such as immunoregulation, growth modulation, and cell differentiation. Aim: To evaluate stromal immunostaining of TNF-α and its receptors (TNFR1 and TNFR2) in malignant ovarian neoplasms, comparing it with benign ovarian neoplasms and non neoplastic ovarian lesions. Materials and Methods: A cross-sectional study was carried out at the Department of Gynaecology and Obstetrics, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil, from January 1997 to December 2020. Patients with ovarian lesions who underwent surgical treatment according to preestablished criteria (n=95) were included in the study. Patients with benign (n=37) and malignant (n=43) ovarian epithelial neoplasms, and non neoplastic ovarian lesions (n=15) were included. Data evaluated included age, parity, hormonal status (menarche or menopause), histological grade, and staging. Immunohistochemical study was performed to evaluate stromal TNF-α, TNFR1, and TNFR2. Data were analysed by GraphPad Prism 6 and IBM Statistical Package for the Social Sciences (SPSS) Statistics 20.0 software. The comparison between non neoplastic tumours, benign and malignant neoplasms was performed by the Fisher’s exact test with a significance level below 0.05. Results: Considering staining intensity 0 and 1 as “weak immunostaining” and 2 and 3 as “strong immunostaining,” TNF-α stromal immunostaining was stronger (2/3) in benign ovarian neoplasms compared to non neoplastic tumours (p-value=0.0016) and in malignant neoplasms compared to non neoplastic tumours (p-value<0.0001). TNFR1 immunostaining was stronger (2/3) in the stroma of malignant neoplasms compared to benign neoplasms (p-value<0.0001) and stronger (2/3) when comparing benign neoplasms with non neoplastic ovarian lesions (p-value=0.0002). For TNFR2, stromal immunostaining was stronger (2/3) in malignant neoplasms compared to benign neoplasms (p-value =0.0091) and stronger in malignant neoplasms compared to non neoplastic lesions (p-value=0.0004). Conclusion: A stronger immunostaining for TNF-α and its receptors was found in ovarian cancer, suggesting that they may be targets for further studies to verify their role in carcinogenesis and the progression of ovarian neoplasms. A better understanding of the role of TNF-α and its receptors in the tumour stroma of ovarian tumours may lead to future studies that may clarify the mechanisms of carcinogenesis and tumour progression.
- 1 July 2024
- Published by JCDR Research and Publications in Journal of Clinical and Diagnostic Research
- Vol. 18 (7) , XC11-XC15
Differences in Stromal Immunostaining of Tumour Necrosis Factor-alpha and its Receptors in Neoplastic and Non Neoplastic Ovarian Lesions: A Cross-sectional Study
Introduction: Ovarian cancer has an unknown pathogenesis, and cytokines may play an important role in the aetiology and prognosis. Tumour Necrosis Factor-alpha (TNF-α) and its receptors (TNFR1 and TNFR2) are involved in the biology of ovarian cancer, tumour pathogenesis, and their relationship with prognostic factors. They are involved in biological processes such as immunoregulation, growth modulation, and cell differentiation. Aim: To evaluate stromal immunostaining of TNF-α and its receptors (TNFR1 and TNFR2) in malignant ovarian neoplasms, comparing it with benign ovarian neoplasms and non neoplastic ovarian lesions. Materials and Methods: A cross-sectional study was carried out at the Department of Gynaecology and Obstetrics, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil, from January 1997 to December 2020. Patients with ovarian lesions who underwent surgical treatment according to preestablished criteria (n=95) were included in the study. Patients with benign (n=37) and malignant (n=43) ovarian epithelial neoplasms, and non neoplastic ovarian lesions (n=15) were included. Data evaluated included age, parity, hormonal status (menarche or menopause), histological grade, and staging. Immunohistochemical study was performed to evaluate stromal TNF-α, TNFR1, and TNFR2. Data were analysed by GraphPad Prism 6 and IBM Statistical Package for the Social Sciences (SPSS) Statistics 20.0 software. The comparison between non neoplastic tumours, benign and malignant neoplasms was performed by the Fisher’s exact test with a significance level below 0.05. Results: Considering staining intensity 0 and 1 as “weak immunostaining” and 2 and 3 as “strong immunostaining,” TNF-α stromal immunostaining was stronger (2/3) in benign ovarian neoplasms compared to non neoplastic tumours (p-value=0.0016) and in malignant neoplasms compared to non neoplastic tumours (p-value<0.0001). TNFR1 immunostaining was stronger (2/3) in the stroma of malignant neoplasms compared to benign neoplasms (p-value<0.0001) and stronger (2/3) when comparing benign neoplasms with non neoplastic ovarian lesions (p-value=0.0002). For TNFR2, stromal immunostaining was stronger (2/3) in malignant neoplasms compared to benign neoplasms (p-value =0.0091) and stronger in malignant neoplasms compared to non neoplastic lesions (p-value=0.0004). Conclusion: A stronger immunostaining for TNF-α and its receptors was found in ovarian cancer, suggesting that they may be targets for further studies to verify their role in carcinogenesis and the progression of ovarian neoplasms. A better understanding of the role of TNF-α and its receptors in the tumour stroma of ovarian tumours may lead to future studies that may clarify the mechanisms of carcinogenesis and tumour progression.
- 22 April 2024
- Published by Care Comm in Česká gynekologie
- Vol. 89 (2) , 95-101
Peritumoral stroma and systemic inflammatory response in cervical cancer
Objective: To compare cervical stroma in advanced cervical cancer with the control group; to compare, in the pre-treatment period, hemogram parameters in patients with advanced cervical cancer with the same parameters as the control group; and to verify if there is an association of stromal markers with prognostic factors in cervical cancer. Materials and methods: We prospectively evaluated 16 patients diagnosed with advanced invasive cervical cancer. A control group of 22 patients was used (uterine leiomyoma). Immunohistochemistry was performed to verify the stromal immunostaining of alpha-smooth muscle actin (SMA) and fibroblast activation protein alpha (FAP). Immunostainings and hemogram parameters were compared using Fisher's exact and Mann-Whitney Test, respectively. Results: Strong FAP immunostaining was more frequent in patients with cervical cancer when compared with patients with leiomyoma (P = 0.0002). Regarding SMA, strong immunostaining was also found more in the group of cancer patients compared to the control group (P < 0.00001). The neutrophil-lymphocyte ratio (NLR) values were higher in the cancer patient group compared to the control group (P = 0.0019). There was no association of the parameters studied with prognostic factors. Conclusions: Strong FAP and SMA immunostaining was found more in patients with cervical cancer when compared to the control group. NLR values were also higher in cervical cancer. Key words: uterine cervical neoplasms – alpha-smooth muscle actin – fibroblast activation protein alpha – blood cell count
- 22 April 2024
- Published by Care Comm in Česká gynekologie
- Vol. 89 (2) , 95-101
Peritumoral stroma and systemic inflammatory response in cervical cancer
Objective: To compare cervical stroma in advanced cervical cancer with the control group; to compare, in the pre-treatment period, hemogram parameters in patients with advanced cervical cancer with the same parameters as the control group; and to verify if there is an association of stromal markers with prognostic factors in cervical cancer. Materials and methods: We prospectively evaluated 16 patients diagnosed with advanced invasive cervical cancer. A control group of 22 patients was used (uterine leiomyoma). Immunohistochemistry was performed to verify the stromal immunostaining of alpha-smooth muscle actin (SMA) and fibroblast activation protein alpha (FAP). Immunostainings and hemogram parameters were compared using Fisher's exact and Mann-Whitney Test, respectively. Results: Strong FAP immunostaining was more frequent in patients with cervical cancer when compared with patients with leiomyoma (P = 0.0002). Regarding SMA, strong immunostaining was also found more in the group of cancer patients compared to the control group (P < 0.00001). The neutrophil-lymphocyte ratio (NLR) values were higher in the cancer patient group compared to the control group (P = 0.0019). There was no association of the parameters studied with prognostic factors. Conclusions: Strong FAP and SMA immunostaining was found more in patients with cervical cancer when compared to the control group. NLR values were also higher in cervical cancer. Key words: uterine cervical neoplasms – alpha-smooth muscle actin – fibroblast activation protein alpha – blood cell count
- Open Access
- 23 October 2023
- Published by Archives of Health Investigation in ARCHIVES OF HEALTH INVESTIGATION
- Vol. 12 (10) , 1975-1978
HPV and Systemic Response in Cervical Intraepithelial Neoplasia
Objectives: to verify whether there is an association of low and high-risk HPV with blood count parameters in patients with cervical intraepithelial neoplasia. Methods: We prospectively evaluated 48 patients with Pap smear showing low or high-grade intraepithelial lesion, submitted to collection of material to perform PCR for high-risk and low-risk HPV. The following blood count parameters were evaluated: hemoglobin, red blood cells, hematocrit, absolute number of leukocytes, neutrophils, lymphocytes, eosinophils, basophils, monocytes and platelets, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and Red Cell Distribution Width (RDW). Receiver operating characteristic (ROC) curve was used to obtain the area under the curve (AUC) relating the positivity or not of HPV with the blood count parameters evaluated. Mann-Whitney test and multivariate analysis were performed, with level of significance less than 0.05. Results: Relating the positivity or not of HPV with the blood count parameters (Roc curves), there was statistical significance only between high-risk HPV and the platelet count (sensitivity=75%, specificity=66.7%, AUC=0.674, p=0.039). Platelet count ≤ 177,000/mm3 is associated with high-risk HPV. Subsequently, the multivariate analysis was performed, and the absolute value of platelets was considered an independent variable in this association with high-risk oncogenic HPV. Conclusion: A systemic response is found with the presence of high-risk HPV in CIN. Thus, platelet count ≤ 177,000/mm3 is associated with high-risk HPV.
- 23 October 2023
- Published by Archives of Health Investigation in ARCHIVES OF HEALTH INVESTIGATION
- Vol. 12 (10) , 1975-1978
Open AccessHPV and Systemic Response in Cervical Intraepithelial Neoplasia
Objectives: to verify whether there is an association of low and high-risk HPV with blood count parameters in patients with cervical intraepithelial neoplasia. Methods: We prospectively evaluated 48 patients with Pap smear showing low or high-grade intraepithelial lesion, submitted to collection of material to perform PCR for high-risk and low-risk HPV. The following blood count parameters were evaluated: hemoglobin, red blood cells, hematocrit, absolute number of leukocytes, neutrophils, lymphocytes, eosinophils, basophils, monocytes and platelets, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and Red Cell Distribution Width (RDW). Receiver operating characteristic (ROC) curve was used to obtain the area under the curve (AUC) relating the positivity or not of HPV with the blood count parameters evaluated. Mann-Whitney test and multivariate analysis were performed, with level of significance less than 0.05. Results: Relating the positivity or not of HPV with the blood count parameters (Roc curves), there was statistical significance only between high-risk HPV and the platelet count (sensitivity=75%, specificity=66.7%, AUC=0.674, p=0.039). Platelet count ≤ 177,000/mm3 is associated with high-risk HPV. Subsequently, the multivariate analysis was performed, and the absolute value of platelets was considered an independent variable in this association with high-risk oncogenic HPV. Conclusion: A systemic response is found with the presence of high-risk HPV in CIN. Thus, platelet count ≤ 177,000/mm3 is associated with high-risk HPV.
- Open Access
W Prime: Evidence-Based Proposal for a New Predictor of Gait Speed in Older Women
Background: The hyperbolic torque-duration curve depicts critical torque (CT) and W prime (W′), with the curve’s asymptote representing CT as the boundary between heavy- and severe-intensity domains. W′, the curvature constant, indicates cumulative work beyond CT. This study investigated age-related reductions in W′, CT, and gait speed, and whether W′ and CT predict gait speed independently of muscle torque. Methods: three groups (adults, middle-aged, older) totaling 131 women were studied. W′ and CT were determined using 60 maximal isometric voluntary contractions of knee extensors. The fast gait speed was calculated in walking tests at 10 m, 400 m, and six minutes (6 MWT). Results: gait speed decreased (p < 0.05) with age, as did W′ and CT. Both W′ and CT correlated positively with gait speed at different distances (10 m, 400 m, 6 MWT). Adjusted for maximum muscle torque, only W′ maintained a positive association (p < 0.05) with all gait speed tests (10 m: β = 0.201, SE = 0.086; 400 m: β = 0.262, SE = 0.085; 6 MWT: β = 0.187, SE = 0.086). Conclusions: aging led to declines in W′, CT, and gait speed. W′, not CT, remained a significant predictor of gait speed, indicating its importance for older women’s mobility.
Open AccessW Prime: Evidence-Based Proposal for a New Predictor of Gait Speed in Older Women
Background: The hyperbolic torque-duration curve depicts critical torque (CT) and W prime (W′), with the curve’s asymptote representing CT as the boundary between heavy- and severe-intensity domains. W′, the curvature constant, indicates cumulative work beyond CT. This study investigated age-related reductions in W′, CT, and gait speed, and whether W′ and CT predict gait speed independently of muscle torque. Methods: three groups (adults, middle-aged, older) totaling 131 women were studied. W′ and CT were determined using 60 maximal isometric voluntary contractions of knee extensors. The fast gait speed was calculated in walking tests at 10 m, 400 m, and six minutes (6 MWT). Results: gait speed decreased (p < 0.05) with age, as did W′ and CT. Both W′ and CT correlated positively with gait speed at different distances (10 m, 400 m, 6 MWT). Adjusted for maximum muscle torque, only W′ maintained a positive association (p < 0.05) with all gait speed tests (10 m: β = 0.201, SE = 0.086; 400 m: β = 0.262, SE = 0.085; 6 MWT: β = 0.187, SE = 0.086). Conclusions: aging led to declines in W′, CT, and gait speed. W′, not CT, remained a significant predictor of gait speed, indicating its importance for older women’s mobility.